Aptevo Therapeutics (NASDAQ:APVO) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Aptevo Therapeutics (NASDAQ:APVO) to a sell rating in a research report released on Saturday morning.

Aptevo Therapeutics Stock Up 1.3 %

APVO opened at $2.41 on Friday. Aptevo Therapeutics has a 12-month low of $2.35 and a 12-month high of $207.33. The business has a 50 day moving average of $3.85 and a 200-day moving average of $171.77.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.